
Nano-X Imaging (NNOX) Stock Forecast & Price Target
Nano-X Imaging (NNOX) Analyst Ratings
Bulls say
Nano X Imaging Ltd reported a revenue growth of $3.0 million in Q3 2024, marking an increase from $2.5 million in Q3 2023, primarily driven by expansion in its teleradiology services and AI solutions. The company is set to present new clinical data at ECR 2025, further enhancing its positioning in the advanced imaging market, and fulfilling strong demand for high-quality, cost-effective imaging solutions across Europe. Strategic partnerships with significant players such as Fujifilm and SK Telecom bolster its market penetration and distribution capabilities, while collaborations demonstrating superior diagnostic performance highlight the transformative potential of its AI-driven technologies.
Bears say
Nano X Imaging Ltd faces significant challenges that underpin a negative outlook for its stock. The healthcare provider resistance to adopting new technology over established systems, coupled with skepticism regarding the scalability and efficacy of its products, could result in a slower-than-expected uptake and ultimately hinder revenue generation. Furthermore, operational execution issues, regulatory hurdles, and potential future legal challenges may impede the company's ability to commercialize its offerings and negatively impact its financial stability.
This aggregate rating is based on analysts' research of Nano-X Imaging and is not a guaranteed prediction by Public.com or investment advice.
Nano-X Imaging (NNOX) Analyst Forecast & Price Prediction
Start investing in Nano-X Imaging (NNOX)
Order type
Buy in
Order amount
Est. shares
0 shares